Ryan G. Casner

Dec 5, 2024 | biorxiv.org | Qian Wang |Yicheng Guo |Ryan G. Casner |Jian Yu

AbstractSARS-CoV-2 has largely evolved to resist antibody pressure, with each successive viral variant becoming more and more resistant to serum antibodies in the population. This evolution has rendered inactive all therapeutic monoclonal antibodies previously authorized, and it is now threatening the remaining clinical product for immunoprophylaxis against COVID-19.